.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,685,998

« Back to Dashboard

Claims for Patent: 8,685,998

Title:Tacrolimus for improved treatment of transplant patients
Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
Inventor(s): Gordon; Robert D. (Sandy Springs, GA), Holm; Per (Vanlose, DK), Lademann; Anne-Marie (Klampenborg, DK), Norling; Tomas (Lyngby, DK)
Assignee: Veloxis Pharmaceuticals A/S (Horsholm, DK)
Application Number:12/499,034
Patent Claims: 1. An extended release oral dosage form for once daily immunosuppressive treatment of a patient in need thereof, comprising tacrolimus as an active substance, wherein (a) at least 8% of the active substance is released at the 4 hour time point, (b) less than 25% of the active substance is released at the 5 hour time point, (c) 40% of the active substance is released within 10 to 14 hours, (d) 63.5% or less of the active substance is released at the 12 hour time point, and (e) the dosage form releases the active substance with a substantial zero order release profile over an extended period of time defined by the release from the 8 hours time point to the 15 hours time point, the substantial zero order release being defined as a linear release profile with a deviation of at the most +/-15%, when tested according to the USP II dissolution test (paddle) or USP I dissolution test (basket) method at a rotation of 50 rpm in a medium at pH 4.5 comprising 0.005% hydroxypropylcellulose.

2. The extended release oral dosage form according to claim 1, wherein 63.5% or less of the active substance is released when measured at the 20 hour time point.

3. The extended release oral dosage form according to claim 1, wherein 20% w/w of the active substance or less is released within 1 hour.

4. The extended release dosage form according to claim 1, wherein the active substance is present as a molecular dispersion.

5. The extended release dosage form according to claim 1, wherein the release of the active substance is controlled by the dissolution or erosion of a polymer.

6. The extended release oral dosage form according to claim 1, which when administered once daily in steady state to a healthy subject or a patient, the swing of the blood concentrations of tacrolimus measured as (C.sub.max-C.sub.min)/C.sub.min is less than the swing observed when administering either the Advagra.RTM. (approved by the European Agency for the Evaluation of Medicinal Products (EMEA) on Apr. 23, 2007) or Prograf.RTM. (approved under U.S. New Drug Application No. 050708) dosage form or a bioequivalent extended release dosage form of tacrolimus in a once daily regimen and being determined under similar conditions and administered in similar molecular daily dosages of the tacrolimus.

7. The extended release dosage form according to claim 1, wherein the active substance is present in a hydrophilic or water-miscible vehicle wherein the vehicle is selected from the group consisting of a polyethylene glycol, a polyoxyethylene oxide, poloxamer, polyoxyethylene stearate, poly-epsilon caprolactone, polyglycolized glycerides, polyvinylpyrrolidone, polyvinyl-polyvinylacetate copolymer, polyvinyl alcohol, polymethacrylic polymer hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethylcellulose, hydroxyethyl cellulose, a pectin, a cyclodextrin, galactomannan, alginate, carragenate, xanthan gum, and mixtures thereof.

8. The extended release dosage form according to claim 7, wherein the vehicle comprises a mixture of polyethylene glycol (PEG) and poloxamer.

9. The extended release dosage form according to claim 8, wherein the mixture comprises a polyethylene glycol and a poloxamer in a proportion of between 1:3 and 10:1.

10. A method for providing immunosuppressive treatment of a patient in need thereof, comprising administering to the patient in a once daily regimen, the dosage form of claim 1.

11. The method according to claim 10 for the treatment or prevention of delayed rejection.

12. The method according to claim 10, for the treatment or prevention of acute rejection.

13. The method according to claim 10, wherein the patient suffers from peak concentration related side effects, where the side effect is development of hypertension.

14. A method for initial treatment of a de novo organ transplant patient with tacrolimus comprising administering the dosage form of claim 1 once a day, wherein the oral dosage form provides a systemic exposure on day 1 which is at least 50% of the exposure obtained at day 1 after administration of the same daily dose administered as an immediate release oral dosage form of tacrolimus administered twice a day.

15. The method of claim 14, wherein the oral dosage form provides a systemic exposure on day 1 which is at least 100% of the exposure obtained at day 1 after administration of the same daily dose administered as an extended release oral dosage form releasing more than 30% of the tacrolimus within 5 hours.

16. The method according to claim 14, wherein Tmax on day 1 of the treatment is between 4 hours and 24 hours.

17. The extended release oral dosage form of claim 1, wherein 40% of the active substance is released within 11 to 13 hours, when tested according to the USP II dissolution test (paddle) or USP I dissolution test (basket) method at a rotation of 50 rpm in a medium at pH 4.5 comprising 0.005% hydroxypropylcellulose.

18. The extended release oral dosage form of claim 1, wherein 50% of the active substance is released within 13 to 17 hours, when tested according to the USP II dissolution test (paddle) or USP I dissolution test (basket) method at a rotation of 50 rpm in a medium at pH 4.5 comprising 0.005% hydroxypropylcellulose.

19. The extended release oral dosage form of claim 1, wherein 50% of the active substance is released within 14 to 16 hours, when tested according to the USP II dissolution test (paddle) or USP I dissolution test (basket) method at a rotation of 50 rpm in a medium at pH 4.5 comprising 0.005% hydroxypropylcellulose.

20. An extended release oral dosage form for once daily immunosuppressive treatment of a patient in need thereof, comprising tacrolimus as an active substance, wherein (a) at least 8% of the active substance is released at the 4 hour time point, (b) less than 25% of the active substance is released at the 5 hour time point, (c) 50% of the active substance is released within 13 to 17 hours, (d) 63.5% or less of the active substance is released at the 12 hour time point, and (e) the dosage form releases the active substance with a substantial zero order release profile over an extended period of time defined by the release from the 8 hours time point to the 15 hours time point, the substantial zero order release being defined as a linear release profile with a deviation of at the most +/-15%, when tested according to the USP II dissolution test (paddle) or USP I dissolution test (basket) method at a rotation of 50 rpm in a medium at pH 4.5 comprising 0.005% hydroxypropylcellulose.

21. The extended release oral dosage form of claim 20, wherein 50% of the active substance is released within 14 to 16 hours, when tested according to the USP II dissolution test (paddle) or USP I dissolution test (basket) method at a rotation of 50 rpm in a medium at pH 4.5 comprising 0.005% hydroxypropylcellulose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc